AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for ATP-binding cassette sub-family C member 8

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q09428

UPID:

ABCC8_HUMAN

Alternative names:

Sulfonylurea receptor 1

Alternative UPACC:

Q09428; A6NMX8; E3UYX6; O75948; Q16583

Background:

ATP-binding cassette sub-family C member 8, also known as Sulfonylurea receptor 1, plays a pivotal role as a subunit of the beta-cell ATP-sensitive potassium channel (KATP). This protein is a crucial regulator of ATP-sensitive K(+) channels and insulin release, integral to maintaining glucose homeostasis.

Therapeutic significance:

The protein's malfunction is linked to several metabolic disorders, including Leucine-induced hypoglycemia, Hyperinsulinemic hypoglycemia, familial, 1, Permanent neonatal diabetes mellitus, 3, and Transient neonatal diabetes mellitus 2. These associations underscore its potential as a target for therapeutic interventions aimed at treating these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.